BMJ Open

Initiation rates of statin therapy for the primary prevention of cardiovascular disease: an assessment of differences between countries of the UK and between regions within England

Aidan G O’Keeffe,1 Irene Petersen,2 Irwin Nazareth2

ABSTRACT

Objectives: To investigate the extent to which variation exists in the initiation rate of statin therapy for the primary prevention of cardiovascular disease between countries of the UK and between different regions within England. Design: Cohort study using data from a large UK primary care database. Setting: UK. Participants: 4 820 885 individuals from 554 general practitioner (GP) practices during the period 2004–2012. Main outcome measures: Rate of statin therapy initiation per 1000 person-years. Results: Relative to a fixed English rate of 1 initiation per 1000 person-years and accounting for gender, age and social deprivation level, the rate was similar for Scotland at 0.92 (95% CI 0.84 to 1.00) and rates for Northern Ireland and Wales were higher at 1.40 (95% CI 1.20 to 1.62) and 1.18 (95% CI 1.05 to 1.32), respectively. Within England, the regions could be classified into three groups with respect to statin therapy initiation rates (relative to a rate of 1 initiation per 1000 person-years for London): the South Central 0.73 (95% CI 0.64 to 0.83), South West 0.80 (95% CI 0.71 to 0.91), East of England 0.81 (95% CI 0.71 to 0.94) and South East Coast 0.83 (95% CI 0.73 to 0.95); strategic health authorities had similar low rates followed by the East Midlands 0.88 (95% CI 0.73 to 1.05), West Midlands 0.96 (95% CI 0.84 to 1.09), North East 0.96 (95% CI 0.79 to 1.16), Yorkshire and Humber 0.97 (95% CI 0.81 to 1.17) and London strategic health authorities. North West England exhibited the highest rate of statin therapy initiation of 1.16 (95% CI 1.02 to 1.31).

Conclusions: Considerable variation in the rate of statin therapy initiation was observed between the four countries of the UK and between different geographical regions within England.

INTRODUCTION

Statin therapy is a class of lipid-modifying drugs, commonly prescribed in UK primary care. Statins were first developed during the 1970s and the first commercially marketed statin, simvastatin, was introduced in the UK in the late 1980s. Since then, and following results from several clinical trials, statins have become one of the most routinely prescribed class of drugs in the UK. The National Institute for Health and Care Excellence (NICE) issues guidelines on the prescription of statins for UK general practitioners (GP). In January 2006, NICE recommended that statin therapy should be initiated for the primary prevention of cardiovascular disease (CVD) in adults aged under 75 years whose 10-year risk of developing CVD, as calculated using an appropriate risk score (eg, the Framingham risk score or QRISK score), exceeds 20%. In addition, NICE recommended that individuals aged over 75 years could be considered at risk of CVD regardless of their 10-year CVD risk.
score and that statin therapy should be considered for this age group, particularly for individuals at risk such as smokers or hypertensives. Recently, NICE has changed these guidelines and suggested that a 10% CVD risk rule be implemented for the prescription of statins in the under 75s.

Despite the increasing public awareness of the clinical benefits of statins within the UK, there have been relatively few attempts to assess the level of initiation of statin therapy for the primary prevention of CVD within the UK population. Some studies have examined trends in statin prescription within UK general practice, but these were performed using relatively small data sets from the 1990s and early 2000s. Statin prescription trends for the secondary prevention of CVD have also been examined using small observational studies. Other studies have examined trends in the prescription of statins within Europe, without a specific focus on prescription practice within the UK. Recently, there have been some small observational studies concerning statin prescriptions within the UK, but a recent large-scale analysis of the initiation rates of statin therapy within the UK population has not been undertaken.

Electronic health records in UK primary care allow a more thorough examination of statin use. We use such data to perform an analysis of statin therapy initiation rates for the primary prevention of CVD within the UK population from 2004 to 2012. Our principal aim is to examine whether there is any variation in the rate of initiation of statin therapy between the four UK countries and the extent to which any differences observed can be explained by demographic and/or socioeconomic factors. Furthermore, within England, we examine the extent to which statin therapy initiation rates vary between different regions.

**DATA AND METHODS**

**THIN database**

We used data from The Health Improvement Network (THIN) database (http://www.thin-uk.com), one of the largest sources of UK primary care data. The database contains anonymised patient records collected at over 500 UK general practices, including patient demographics, consultation information and patient therapy records, linked over time. Over 98% of the UK population are registered with a general practice and THIN is regarded as broadly representative of the general UK population. The database also includes information on the Townsend score, a measure of social deprivation, categorised into five quintiles from one (least deprived) to five (most deprived).

**Our study**

We chose to examine statin initiation levels in individuals with no history of CVD events during the period 2004–2012. We chose to begin our analyses in 2004 because of the introduction of the Quality and Outcomes Framework (QOF) at that time. Patients who initiated statins within 6 months of their date of registration at a practice were excluded. This was done in an effort to ensure that patients who moved practice and who had previously initiated statin therapy would not be included. The use of a 6-month ‘qualification period’ appears reasonable, since the vast majority of individuals receive statins on monthly or at most three monthly prescriptions and a 6-month ‘qualification period’ has been used in other studies that used THIN. The principal outcome of interest is the number of statin therapy initiations during the time period 2004–2012. Time is accounted for explicitly by measuring the total patient time ‘at risk’ (where ‘at risk’ implies ‘eligible for statin therapy initiation’) during this period and the time until first statin prescription or end of follow-up at the patient level. Important patient level and practice level variables such as gender, age, Townsend score quintile, UK country and strategic health authority (SHA; English practices) were also recorded. We note that SHAs were abolished in March 2013; however, we feel that SHAs remain a useful variable for a comparison of English regions.

**Statistical analyses**

The main outcome of interest is the statin therapy initiation rate per 1000 person-years. For each individual, the person-years of follow-up were calculated as running from the latest of: 18th birthday, practice registration date or 1 January 2004 to the earliest of: date of first statin prescription, date of death, date of first CVD event, date of transfer from practice or 31 December 2012. As such, only those adult patients who had neither experienced a CVD event nor had previously been prescribed statins were included. The statin therapy initiation rate was estimated both within each practice and using data from all practices. Furthermore, statin therapy initiation rates were estimated within each country of the UK and for each strategic health authority within England.

We used Poisson regression models, with log (person-years at risk) as an offset term, to estimate the rate of statin therapy initiation with regard to gender, age group and Townsend score quintile. To account for clustering of individuals within practices, we included practice level random effects. Age was classified into 12 groups according to age in years (18–39, 40–49, 50–54, 55–59, 60–64, 65–69, 70–75, 75–80, 80–85, 85–90, 90–95 and 95+). English practices contributed the majority of data and so we felt that it was appropriate to examine possible differences in statin therapy initiation rates between different regions of England. Before 1 April 2013, primary care within England was governed by 10 SHAs: London, East Midlands, West Midlands, East of England, North East England, North West England, South Central, South East Coast, South West England and Yorkshire and Humber. Although SHAs have since been replaced by smaller clinical commissioning groups, the SHAs existed while our data were collected and we feel that a
comparison of rates between different SHAs could be important in highlighting possible differences in statin therapy initiation rates within England. Table 1 summarises the number of practices within the different SHAs in our data.

Data manipulation was carried out using STATA V.13 with other statistical analyses, including all modelling, undertaken using the R statistical package (V.3.0.2).

RESULTS
We analysed data from 554 GP practices across the UK (by country: England: 406, Northern Ireland: 23, Scotland: 85, Wales: 40) using records from 4 820 885 individuals. Table 2 provides a summary of cohort demographics stratified by UK country. There were slightly more females than males included in our analyses, possibly because, in general, females are more likely than males to consult their GP regularly.27 Age at cohort entry was broadly similar between countries. We see that, across all countries, there were similar proportions of patients in Townsend score quintiles 2–4 with slightly larger and smaller proportions in quintiles 1 and 5, respectively. This distribution of Townsend score quintiles is seen within England but not for the other countries of the UK, with Northern Ireland, Scotland and Wales tending to have higher proportions of patients in more deprived Townsend score quintiles.

Figure 1 shows a plot of the estimated statin therapy initiation rate by practice, with a solid red line showing the mean estimated statin therapy initiation rate using data from all practices and the dashed red lines showing this mean ±2SD(sample SD). Although many practices have estimated initiation rates close to the overall mean rate of 14.91 per 1000 person-years, there exists substantial variation in rates between different practices, with estimated initiation rates ranging from 0.83 to 38.26 initiations per 1000 patient-years. Seven practices have a rate lower than two sample SDs below the estimated mean initiation rate and 28 practices have a rate greater than two sample SDs above the estimated mean initiation rate. Figure 2 shows a similar plot, but with practices grouped according to UK country. Practices within England and Scotland yield very similar mean estimated initiation rates, whereas those in Northern Ireland and Wales have a slightly higher mean estimated initiation rate. In addition, variation in estimated rates appears slightly smaller within Northern Ireland, although we note the smaller number of Northern Irish practices.

Table 3 shows results from fitted models. A comparison of the adjusted and unadjusted initiation rates shows that even after accounting for patient demographics, initiation rates within Northern Ireland and Wales are greater than that in England, whereas the rate in Scotland is slightly lower than that in England.

Regions within England
Figure 3 shows a plot of the estimated statin therapy initiation rate by practice within England, but with practices grouped according to SHA. Solid red horizontal lines denote the within SHA mean initiation rate and red dashed lines denote a mean ±2SD(sample SD) for initiation rate within each SHA. This plot shows that there is considerable variation in initiation rates between practices within each region. Table 4 provides a numerical comparison of estimated initiation rates, with a practice-specific random effect to account for the clustering of patients within practices. Prior to adjustment for the demographic variables (columns 2 and 3), we see that observable differences in initiation rates exist between the different SHAs, with the West Midlands, Yorkshire and Humber, North West and North East SHAs showing slightly higher rates than those seen in London and the South of England. After accounting for demographic variables (column 4), these differences are less marked, although the North West region appears to have a significantly higher initiation rate when compared to London. Furthermore, the East of England, South Central, South East Coast and South West SHAs exhibit significantly lower initiation rates when compared to the London, East Midlands, West Midlands, Yorkshire and Humber and North East SHAs, even after accounting for demographic variables.

Gender, age group and Townsend score quintile
Finally, we examined the statin therapy initiation rates controlling for gender, age group and the Townsend score quintile, including a practice level random effect. Table 5 provides a summary of these results. For age group, we see that the initiation rate generally increases with age, and this occurs until patients reach 75 years whence rates begin to decrease. Males tend to have higher estimated initiation rates than females. Initiation rates for males appear to decrease slightly as the Townsend score quintile increases (ie, as areas become more socially deprived); however, once age distribution is accounted for (5th main column of Table 5), this trend is no longer seen. Estimated unadjusted statin therapy initiation rates are broadly similar for females across all Townsend score quintiles. However, age-adjusted statin
therapy initiation rates appear to increase in females as the Townsend score quintile increases (ie, as areas become more socially deprived).

**DISCUSSION**

**Findings**

We found considerable variation in statin therapy initiation rates between different practices across the UK. These rates were similar in England and Scotland but in Wales and Northern Ireland were 18% (95% CI 5% to 32%) to 40% (95% CI 20% to 62%) higher, even after accounting for the possible differences in patient demographics and the clustering of patients with practices, between countries. Considerable variation in the initiation rate was observed between different English regions after accounting for differences in patient demographics. The North West of England had a significantly higher initiation rate when compared to London, Yorkshire and Humber, North East England, East Midlands and West Midlands SHAs. Furthermore, the East of England, South Central, South East Coast and South West SHAs had significantly lower estimated initiation rates when compared to this group of SHAs.

Summary statistics have indicated that regional differences in CVD morbidity exist within the UK.\(^{28}\) It is possible that some difference in statin therapy initiation rates may be explained by the difference in underlying CVD risk within the population served by the practices, such as dietary habits, the levels of smoking and diabetes, low-density lipoprotein (LDL) cholesterol level, hypertension and body mass index (BMI) among others. Previous research has shown that differences between practice prescribing rates for statins were positively related to the rate of coronary heart disease (CHD) hospital diagnoses and

**Table 2**

| Variable                  | UK country         | All (4,820,885) |
|---------------------------|--------------------|-----------------|
| Gender counts             | Male (2,312,378)   | Female (2,508,507) |
| Mean age at cohort entry (years) | 40.2               | 40.2             |
| Townsend quintile counts  | 1 (least deprived) | 966,936 (25.35%) |
|                           | 2                   | 776,252 (20.35%) |
|                           | 3                   | 800,856 (21.00%) |
|                           | 4                   | 986,096 (21.44%) |
|                           | 5 (most deprived)   | 702,194 (14.57%) |

**Figure 1** Plot showing the estimated statin therapy initiation rate for each of the 554 general practitioner practices. The solid red line indicates the sample mean statin therapy initiation rate. The dashed red lines indicate this sample mean±2SD(sample SD).
negatively associated with deprivation.\textsuperscript{13, 29, 30} Examining data from 2010, Scotland has a higher rate of myocardial infarction than England, and similarly the North East and North West regions of England have higher rates of myocardial infarction with the South East and East of England reporting the lowest rates.\textsuperscript{28} Although our study focused on statin prescription for primary prevention, our findings concur with some of these observations.

Initiation rates were generally lower in females compared to males and rates tended to increase with age for both genders, until approximately 75 years, after which rates generally declined. After accounting for age group, initiation rates increased slightly as the Townsend score quintile increased for both males and females. The risk of CHD among middle-aged people is 2–5 times more common in males than females, but for both genders the risk of CHD increases with age and the risk of CHD in older males and females is similar.\textsuperscript{31} Our findings suggest that prescribing was lower in women than men across all age groups with the exception of those over 75 years of age who were prescribed statins at the same rate irrespective of their gender. The lower rates of prescribing in the over 75s, despite their heightened risk of CHD, might suggest that primary prevention of CVD in the elderly could be improved. Nevertheless, our findings represent an improvement in practice. A previous recent study suggested that patients over 75 years of age were unlikely to be prescribed a statin for the primary prevention of CVD irrespective of their gender.\textsuperscript{13} It is likely that, with the absence of risk assessment methods in older people, GP could benefit from clearer guidance on risk assessment for people above the age of 75 years.

Our data clearly indicate that initiation of stain therapy increased with deprivation (after accounting for age). Once again, this suggests a change in GPs’

### Table 3  Summary of country results

| Country     | Estimated statin initiation rate (estimated 95% CI) | Unadjusted relative statin initiation rates | Adjusted relative statin initiation rates* |
|-------------|----------------------------------------------------|--------------------------------------------|-------------------------------------------|
| England     | 14.82 (14.37 to 15.28)                             | 1                                          | 1                                         |
| Northern Ireland | 18.52 (16.23 to 21.15)                         | 1.25 (1.09 to 1.43)                         | 1.40 (1.20 to 1.62)                        |
| Scotland    | 14.63 (13.64 to 15.69)                             | 0.99 (0.91 to 1.07)                         | 0.92 (0.84 to 1.00)                        |
| Wales       | 17.06 (15.49 to 18.78)                             | 1.15 (1.04 to 1.27)                         | 1.18 (1.05 to 1.32)                        |

The second column shows unadjusted estimated rates for each country, with the third column showing rates for Scotland, Northern Ireland and Wales relative to a fixed rate of 1 unit per 1000 person-years for England. The fourth column shows these relative rates but where rates are adjusted to account for gender, age group in years and Townsend score quintile.

*Rates adjusted for gender, age group and Townsend score quintile.
prescribing behaviour. Previous data suggested that practices with higher deprivation indices prescribed fewer statins to their patients than those in less deprived practices. However, our findings suggest that these inequalities in prescribing based on deprivation have narrowed since the study by Packham et al.

Strengths and limitations
A clear strength of this study is the large sample size which reflects the general UK population and allows the modelling of quantities of interest, controlled for a range of factor variables, without the problem of small group sizes in the model fitting process. In addition, since most GPs generate prescriptions electronically, the nature of the THIN database allows us to accurately monitor statin prescriptions in a detailed manner, by patient, longitudinally. We feel that this has allowed us to make informed and comprehensive assessment statin therapy initiation rates for primary prevention of CVD, within the UK population.

**Table 4** Estimated statin therapy initiation rates for different strategic health authorities (SHA) within England

| Strategic health authority | Statin initiation rate (estimated 95% CI) | Unadjusted relative statin initiation rate | Adjusted relative statin initiation rate* |
|----------------------------|------------------------------------------|-------------------------------------------|-------------------------------------------|
| London                     | 13.33 (12.31 to 14.43)                   | 1                                         | 1                                         |
| East Midlands              | 15.17 (13.30 to 17.30)                   | 1.14 (0.98 to 1.33)                       | 0.88 (0.73 to 1.05)                       |
| East of England            | 13.91 (12.58 to 15.37)                   | 1.04 (0.92 to 1.19)                       | 0.81 (0.71 to 0.94)                       |
| West Midlands              | 15.76 (14.44 to 17.21)                   | 1.18 (1.05 to 1.33)                       | 0.96 (0.84 to 1.09)                       |
| North East                 | 16.47 (14.17 to 19.15)                   | 1.24 (1.04 to 1.47)                       | 0.96 (0.79 to 1.16)                       |
| North West                 | 18.03 (16.72 to 19.44)                   | 1.35 (1.21 to 1.51)                       | 1.16 (1.02 to 1.31)                       |
| Yorkshire and Humber       | 17.37 (15.07 to 20.01)                   | 1.30 (1.11 to 1.53)                       | 0.97 (0.81 to 1.17)                       |
| South Central              | 12.75 (11.77 to 13.81)                   | 0.96 (0.86 to 1.07)                       | 0.73 (0.64 to 0.83)                       |
| South East Coast           | 13.78 (12.66 to 15.00)                   | 1.03 (0.92 to 1.16)                       | 0.83 (0.73 to 0.95)                       |
| South West                 | 14.99 (13.83 to 16.25)                   | 1.13 (1.00 to 1.26)                       | 0.80 (0.71 to 0.91)                       |

The first column shows overall rate estimates, the second column shows relative statin therapy initiation rates and the third column shows statin therapy initiation rates adjusted for chosen factors. The second column shows unadjusted estimated rates for each SHA, with the third column showing rates for non-London SHAs relative to a fixed rate of 1 unit per 1000 person-years for the London SHA. The fourth column shows these relative rates but where rates are adjusted to account for gender, age group and Townsend score quintile.

*Rates adjusted for gender, age group and Townsend score quintile.
Table 5: Estimated statin therapy initiation rates for age groups and Townsend score quintiles, stratified according to gender

| Age group (years) | Statin initiation rate per 1000 person-years (estimated 95% CI) | Unadjusted relative statin initiation rate | Adjusted relative statin initiation rate* |
|------------------|---------------------------------------------------------------|------------------------------------------|------------------------------------------|
|                  | Males # Females # Males # Females # Males # Females         | Males # Females # Males # Females         | Males # Females # Males # Females         |
| 18–39            | 1.63 (1.56 to 1.70) 0.93 (0.89 to 0.98)                        | 1                                        | 0.57 (0.55 to 0.60)                       |
| 40–49            | 10.79 (10.42 to 11.17) 6.41 (6.18 to 6.65)                      | 6.63 (6.43 to 6.83) 3.94 (3.81 to 4.07) | 6.69 (6.49 to 6.89) 3.98 (3.85 to 4.11) |
| 50–54            | 23.03 (22.23 to 23.86) 15.87 (15.29 to 16.46)                  | 14.15 (13.71 to 14.60) 9.75 (9.43 to 10.08) | 14.31 (13.88 to 14.77) 9.88 (9.56 to 10.21) |
| 55–59            | 34.69 (33.51 to 35.91) 25.36 (24.47 to 26.27)                  | 21.32 (20.68 to 21.98) 15.58 (15.10 to 16.08) | 21.60 (20.95 to 22.26) 15.82 (15.33 to 16.32) |
| 60–64            | 51.63 (49.89 to 53.42) 36.33 (35.08 to 37.61)                  | 31.72 (30.78 to 32.69) 22.32 (21.64 to 23.02) | 32.17 (31.23 to 33.14) 22.68 (22.00 to 23.38) |
| 65–69            | 67.11 (64.82 to 69.47) 48.26 (46.60 to 49.98)                  | 41.24 (39.99 to 42.52) 29.65 (28.75 to 30.59) | 41.80 (40.55 to 43.08) 30.10 (29.19 to 31.03) |
| 70–74            | 70.77 (68.28 to 73.35) 57.43 (55.44 to 59.50)                  | 43.48 (42.12 to 44.89) 35.29 (34.20 to 36.42) | 44.04 (42.68 to 45.46) 35.70 (34.61 to 36.83) |
| 75–79            | 43.64 (41.91 to 45.44) 47.69 (45.95 to 49.51)                  | 26.81 (25.84 to 27.83) 29.31 (28.34 to 30.31) | 27.10 (26.12 to 28.11) 29.52 (28.56 to 30.52) |
| 80–84            | 32.39 (30.89 to 33.97) 34.83 (33.43 to 36.28)                  | 19.90 (19.04 to 20.81) 21.40 (20.61 to 22.22) | 20.06 (19.20 to 20.96) 21.45 (20.67 to 22.26) |
| 85–89            | 22.10 (20.65 to 23.65) 23.54 (22.39 to 24.75)                  | 13.58 (12.71 to 14.50) 14.47 (13.80 to 15.17) | 13.66 (12.80 to 14.57) 14.46 (13.80 to 15.16) |
| 90–94            | 12.47 (10.85 to 14.32) 11.20 (10.26 to 12.24)                  | 7.66 (6.67 to 8.79) 6.88 (6.31 to 7.51) | 7.69 (6.71 to 8.81) 6.88 (6.31 to 7.49) |
| 95+              | 4.51 (2.89 to 7.04) 5.03 (4.08 to 6.21)                        | 2.77 (1.78 to 4.32) 3.09 (2.51 to 3.82) | 2.77 (1.79 to 4.30) 3.09 (2.51 to 3.81) |

| Townsend score quintile | Statin initiation rate per 1000 person-years (estimated 95% CI) | Unadjusted relative statin initiation rate | Adjusted relative statin initiation rate† |
|-------------------------|---------------------------------------------------------------|------------------------------------------|------------------------------------------|
|                         | Males # Females # Males # Females | Males # Females # Males # Females | Males # Females # Males # Females |
| 1                       | 18.15 (17.45 to 18.87) 13.26 (12.72 to 13.82)                  | 1                                        | 0.73 (0.70 to 0.76)                       |
| 2                       | 17.52 (16.82 to 18.24) 13.76 (13.19 to 14.36)                  | 0.97 (0.92 to 1.01) 0.76 (0.72 to 0.79) | 1.01 (1.00 to 1.02) 0.70 (0.69 to 0.72) |
| 3                       | 16.01 (15.35 to 16.70) 13.69 (13.11 to 14.29)                  | 0.88 (0.84 to 0.92) 0.75 (0.72 to 0.79) | 1.02 (1.01 to 1.04) 0.78 (0.76 to 0.79) |
| 4                       | 15.19 (14.52 to 15.88) 14.03 (13.41 to 14.68)                  | 0.84 (0.80 to 0.88) 0.77 (0.74 to 0.81) | 1.05 (1.03 to 1.07) 0.86 (0.85 to 0.88) |
| 5                       | 14.68 (13.93 to 15.46) 14.40 (13.66 to 15.18)                  | 0.81 (0.76 to 0.86) 0.79 (0.75 to 0.84) | 1.07 (1.05 to 1.09) 0.94 (0.92 to 0.96) |

The first column shows overall rate estimates, the second column shows relative statin therapy initiation rates and the third column shows statin therapy initiation rates adjusted for chosen factors.

* Rates adjusted for Townsend score quintile.
† Rates adjusted for age group.
There are limitations to our methods and sample. We are only using data from those who are registered with a GP. However, in the UK, the vast majority of the population is registered with a GP. We have accounted for sociodemographic variables such as age, sex and social deprivation. While these may be strongly correlated to other factors that may determine initiation of statin prescriptions, it is possible that primary initiation of statins may be governed by factors that we have not captured by the sociodemographic variables.

It is possible that the rate of statin therapy initiation is related to measures such as smoking status, BMI, blood pressure and LDL cholesterol level among others. While it may have been desirable, at first sight, to include such variables in our analyses, we bear in mind the limitations of primary care records. In particular, measures such as BMI, blood pressure and LDL cholesterol level are not recorded for all individuals and may be more likely to exist for those patients who visit their GP more regularly than others, or perhaps those who suffer from chronic or recurrent health conditions.\(^{33}\) Naturally, such patients would not be representative of the general UK population and, as such, the inclusion of variables such as these in our analyses might lead to substantial biases. Conversely, basic demographic variables, such as age group, gender and social deprivation status (taken from a patient’s postcode), are available for the vast majority of individuals who are registered with a GP, irrespective of any health conditions exhibited by a patient, thereby justifying the use of such variables in our analyses.

**Final conclusions**

There is a considerable variation in the rate of initiation of statins for primary prevention of CVD in 4 UK countries and the 10 English regions. However, at the individual level, there is insufficient evidence to suggest that inequalities in prescribing exist between the sexes and across various levels of deprivation. GP may benefit from guidance on statin prescribing in people above the age of 75 years.

**Contributors** AGO led the analysis of the data and the writing of the manuscript and is the guarantor. IP and IN had the idea for the research and AGO led the analysis of the data and the writing of the manuscript and is the guarantor. IP and IN had the idea for the research and AGO led the analysis of the data and the writing of the manuscript and is the guarantor.

**Funding** All authors received funding through grant MR/K014838/1 from the Medical Research Council.

**Ethics approval** The THIN scheme for obtaining and providing anonymous patient data to researchers was approved by the National Health Service South-East Multicentre Research Ethics Committee (MREC) in 2002. Approval for this study was obtained from the Scientific Review Committee on 6 August 2014.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** The analysis code is available from the corresponding author: a.o.keefe@ucl.ac.uk.

**Open Access** This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

**REFERENCES**

1. Baigent C, Keech A, Kearney PM. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78.
2. Endo A, Kuroda M, Tsujita Y, ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J Antibiot (Tokyo) 1976;29:1346–8.
3. Endo A, Monacolin K, a new hypcholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 1979;32:852–4.
4. Pedersen TR, Toft A, Simvastatin: a review. Expert Opin Pharmacother 2004;5:2583–96.
5. [No authors listed] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301–8.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.
8. Brugs J, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
9. Trusler D. Statin prescriptions in UK now total a million each week. BMJ 2011;343:d3450.
10. NICE: Developed by the National Collaborating Centre for Primary Care. Clinical guideline: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular diseases. NICE Clinical Guideline 67; 2008.
11. Baxter C, Jones R, Cottens L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ 1998;317:1134–5.
12. Packham C, Pearson J, Robinson J, et al. Use of statins in general practices, 1996–8; cross sectional study. BMJ 2000;320:1583–4.
13. Majeed A, Moser K, Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health 2000;22:275–9.
14. DeWilde S, Carey IM, Bremer SA, et al. Evolution of statin prescribing 1994–2001: a case of agism but not of sexism? Heart Br Card Soc 2003;89:417–21.
15. Wei L, Ebrahim S, Bartlett C, et al. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005;330:821.
16. Carey IM, DeWilde S, Shah SM, et al. Statin use after first myocardial infarction in UK men and women from 1997 to 2006; Who started and who continued treatment? Nutr Metab Cardiovasc Dis 2012;22:400–8.
17. Teeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998–2002. Br J Clin Pharmacol 2005;60:543–7.
18. Walley T, Folino-Gallo P, Stephens P, et al. Trends in prescribing and utilization of statins and other lipid lowering drugs cross Europe 1997–2003. Br J Clin Pharmacol 2005;60:543–7.
19. Bartholomeeusen S, Vandenebroeck JP, Truyers C, et al. Trends in total cholesterol screening and in prescribing lipid-lowering drugs in general practice in the period 1994–2003. BMC Fam Pract 2008;9:39.
20. Ma J, Seghal NL, Ayanian JZ, et al. National trends in statin prescription by coronary heart disease risk category. PLoS Med 2005;2:e123.
21. Ashworth M, Lloyd D, Smith RS, et al. Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner database ‘Quality and Outcomes Framework’ J Public Health (Oxf) 2007;29:40–7.
22. Li S, Mann RD. The VAMP research multi-purpose database in the U.K. J Clin Epidemiol 1995;48:431–43.
23. Blak BT, Thompson M, Dattani H, et al. Generalisability of the health improvement network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inforrn Prim Care 2011;19:251–5.
24. Man SL, Petersen I, Thompson M, et al. Antiepileptic drugs during pregnancy in primary care: a UK Population Based Study. PLoS ONE 2012;7:e52339.
25. Petersen I, McCrea RL, Osborn DJP, et al. Discontinuation of antipsychotic medication in pregnancy: a cohort study. Schizophr Res 2014;159:218–25.
26. Marston L, Nazareth I, Petersen I, et al. Prescribing of antipsychotics in UK primary care: a cohort study. *BMJ Open* 2014;4:e006135.

27. Wang Y, Hunt K, Nazareth I, et al. Do men consult less than women? An analysis of routinely collected UK general practice data. *BMJ Open* 2013;3:e003320.

28. British Heart Foundation Health Promotion Research Group, Department of Public Health, University of Oxford. Coronary heart disease statistics: a compendium of health statistics [Internet]. 2012. http://www.bhf.org.uk/publications/view-publication.aspx?ps=1002097

29. Gibson A, Asthana S, Brigham P, et al. Geographies of need and the new NHS: methodological issues in the definition and measurement of the health needs of local populations. *Health Place* 2002;8:47–60.

30. Ward P, Noyce P, St L. Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. *J Epidemiol Community Health* 2004;58:89–96.

31. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. *Am J Med* 1984;76:4–12.

32. Packham C, Robinson J, Morris J, et al. Statin prescribing in Nottingham general practices: a cross-sectional study. *J Public Health Med* 1999;21:60–4.

33. Marston L, Carpenter JR, Walters KR, et al. Issues in multiple imputation of missing data for large general practice clinical databases. *Pharmacoepidemiol Drug Saf* 2010;19:618–26.

34. Marston L, Carpenter JR, Walters KR, et al. Smoker, ex-smoker or non-smoker? The validity of routinely recorded smoking status in UK primary care: a cross-sectional study. *BMJ Open* 2014;4:e004958.